Skip to main content
Clinical Trials/NCT00662441
NCT00662441
Completed
Phase 4

Open-Label, Multi-Centre, Study of Levitra 10 mg Once a Day in Males With Erectile Dysfunction Was Carried Out in Four Centres Namely Lagos, Port Harcourt, Enuge and Maiduguri at Their University Teaching Hospitals

Bayer0 sites102 target enrollmentSeptember 2003

Overview

Phase
Phase 4
Intervention
Levitra (Vardenafil, BAY38-9456)
Conditions
Erectile Dysfunction
Sponsor
Bayer
Enrollment
102
Primary Endpoint
International Index of Erectile Function- Erectile Function domain
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. An ideal treatment option should be effective and reliable, have minimal side effects, be simple to use and affordable. The purpose was the evaluation of efficacy and safety of 10 mg oral Vardenafil in Nigerian subjects with Erectile Dysfunction (ED).

Registry
clinicaltrials.gov
Start Date
September 2003
End Date
June 2004
Last Updated
16 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Sponsor
Bayer

Eligibility Criteria

Inclusion Criteria

  • Men \>/= 18 years of age
  • Erectile Dysfunction

Exclusion Criteria

  • History of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month
  • Nitrate therapy
  • Other exclusion criteria apply according to the Summary of Product Characteristics

Arms & Interventions

Arm 1

Intervention: Levitra (Vardenafil, BAY38-9456)

Outcomes

Primary Outcomes

International Index of Erectile Function- Erectile Function domain

Time Frame: 8 weeks

Secondary Outcomes

  • Global Assessment Questionnaire (GAQ)(8 weeks)
  • Safety and tolerability(8 weeks)

Similar Trials